Cancer Gene Therapy

tracking system home

author instructions

reviewer instructions

help

tips

journal home

Welcome to the online manuscript submission and tracking system for Cancer Gene Therapy.

Please be sure that your browser is set to accept cookies as our tracking system requires these for proper operation. See 'Tips' for further information. If you are a first time user please read our Instructions to Authors or Reviewers. Experienced users, please remember passwords are case sensitive.

If you experience any problems, please contact the Platform Support Helpdesk.

Please note: there has been a change to the journals page charge structure– please refer to the instructions to authors for more information.

Forgot my login details

Open access
Cancer Gene Therapy is a hybrid journal. Authors can choose to publish using either the subscription publishing route OR via immediate gold Open Access through payment of an article-processing charge (APC).

Authors may need to take specific actions to achieve compliance with funder and institutional open access mandates. If your research is supported by a funder that requires immediate open access (e.g. according to Plan S principles) then you should select the gold OA route, and we will direct you to the compliant route where possible. For authors selecting the subscription publication route, the journal's standard licensing terms will need to be accepted, including self-archiving policies. Those licensing terms will supersede any other terms that the author or any third party may assert apply to any version of the manuscript.